B.Infanti Pharma Grade API is rendered suitable for direct compression by delumping through a 500 μm sieve and blending in a bin blender at 10–20 rpm for 15–30 min. The addition ratio is treated as a variable derived from target dose and die fill weight: a 10.0 mg dose in a 250.0 mg core corresponds to 4.0% w/w, while a 300.0 mg dose in a 500.0 mg core corresponds to 60.0% w/w. Above 60.0% w/w, flowability and compactability of the active compound dominate the blend, and co-processed excipients with plastic deformation behaviour, such as microcrystalline cellulose/lactose composites, are required to avoid capping. A two-stage lubrication approach is applied: magnesium stearate is added at 0.25–0.50% w/w in the final 3–5 min to limit shear sensitivity; levels beyond 1.0% w/w reduce tablet hardness and slow dissolution. Compression is executed on a rotary tablet press with 8–12 stations, pre-compression force 5–10 kN, main compression force 10–25 kN, and turret speed 20–60 rpm. Forced feeder paddles operate at 20–50 rpm to maintain die fill uniformity. Tablet hardness is maintained between 50–120 N depending on API load, friability remains below 0.8% after 100 drops, and disintegration completes within 15 min in 37 °C water. Pre-drying of the API at 40–50 °C is required when moisture exceeds 2.0% w/w; processing above 60% relative humidity increases sticking and weight variability. Compliance thresholds include USP <905> uniformity of dosage units, USP <711> dissolution, Ph. Eur. 2.9.40, ICH Q3D elemental impurities, and residual solvent limits under ICH Q3C. Terminal finished product types are immediate-release uncoated and film-coated tablets, scored tablets, and bilayer tablets where a second active or release phase is required.

Representative direct compression operating ranges for variable API loading:

Why Does Dry Powder Capsule Filling Demand Tight Bulk Density and Flow Control?

In hard shell capsule filling, B.Infanti Pharma Grade API is incorporated after a 1:10 geometric pre-blend with spray-dried lactose monohydrate when the unit dose is below 25.0 mg; this prevents segregation of fine active particles. The final addition ratio is defined by the filled mass per shell and the target dose: for size 0 shells filled to 400.0 mg net weight, a 100.0 mg dose corresponds to 25.0% w/w, and for size 3 shells filled to 180.0 mg, a 10.0 mg dose corresponds to 5.6% w/w. The blend is passed through a 800 μm cone mill to eliminate agglomerates, then mixed in a V-blender at 12–15 rpm for 15–30 min; magnesium stearate is added at 0.5% w/w for 3–5 min. Powder flow is controlled to Carr index 15–25 and bulk density 0.40–0.70 g/mL; values outside this band produce fill weight variability beyond ±3.0% on dosator and tamping-pin capsule machines. Capsule filling is performed on equipment using dosator or tamping pin principles at speeds of 10,000–150,000 capsules/h; inline checkweighers reject units outside ±3.0% of target fill weight. Empty shells are conditioned at 40–50% RH and 20–25 °C to maintain shell moisture 13–16%; below 40% RH shells become brittle, above 60% RH powder may clump. Desiccant canisters are used for hygroscopic API grades. Compliance includes USP <905>, USP <711>, Ph. Eur. 2.9.5 uniformity of mass of single-dose preparations, and stability testing according to 21 CFR 211.166 and ICH Q1A. Terminal finished product types are hard gelatin capsules, HPMC capsules, and capsules with internal enteric coat for delayed release.

Because B.Infanti Pharma Grade API lots with acicular crystal habit or poured bulk density below 0.30 g/mL segregate and generate high dusting in dry processes, wet granulation is used to produce free-flowing granules with a target particle size of 150–850 μm. The addition ratio in the granule blend is calculated as active content per sachet or per dispersible tablet: a 50.0 mg dose in a 1000.0 mg sachet fill corresponds to 5.0% w/w, while a 250.0 mg dose in a 1000.0 mg fill corresponds to 25.0% w/w. Granulation is performed in a high-shear mixer with impeller speed 200–500 rpm, chopper speed 1000–3000 rpm, and binder solution added at 10–20% w/w; binders include polyvinylpyrrolidone K30 at 2.0–5.0% w/w or pregelatinized starch at 5.0–10.0% w/w. Process end point is verified by impeller torque rising to 3.0–6.0 N·m; stopping below this range leaves excessive fines, while exceeding it produces dense granules with retarded dissolution. Wet mass is dried in a fluid bed at inlet air 50–70 °C until loss on drying is 1.0–2.5%, then milled through a 1000 μm screen. Granules are tested for sieve distribution, bulk density, and moisture; dissolution testing follows USP <711> and Ph. Eur. 2.9.3. Residual binder and solvent levels are limited by ICH Q3C, elemental impurities by ICH Q3D, and microbial limits by Ph. Eur. 2.6.12 / USP <61>. The process is sensitive to ambient humidity above 70% RH, which causes overwetting and lump formation; lactose-based binders should not be combined with amine-bearing API at high temperature because Maillard degradation products may form. Terminal finished product types are single-dose sachet granules, bottle-filled oral granules, dispersible tablets, and effervescent granules where pH-neutral fillers substitute for acid-carbonate systems if the active is acid-labile.

Aseptic Injectable Solution Filling and Terminal Sterilisation Limits

Aqueous injection compounding of B.Infanti Pharma Grade API begins by dissolving the active in Water for Injection under Class C conditions; the addition ratio is expressed as solution concentration, typically 1.0–50.0 mg/mL, and is adjusted by dose and fill volume. A 100.0 mg vial fill at 10.0 mL corresponds to 10.0 mg/mL, while a 50.0 mg pre-filled syringe fill at 1.0 mL corresponds to 50.0 mg/mL. Solution pH is adjusted to 4.0–7.0 with hydrochloric acid or sodium hydroxide, and tonicity is set to 280–320 mOsm/kg with sodium chloride at 0.9% w/v or mannitol. Dissolved oxygen is controlled below 0.5 ppm by nitrogen overlay when the active compound contains oxidation-labile groups. The solution is clarified through 0.22 μm polyethersulfone filters and filled on peristaltic or rotary piston lines into vials, ampoules, or pre-filled syringes within a Class A laminar zone meeting ISO 14644-1:2015 Class 5 limits. Terminal sterilisation at 121 °C for 15 min is selected only when thermal degradation under these conditions leaves assay above 98.0% and total degradation products below 1.0%; otherwise aseptic filtration followed by isolated fill is required. Filling accuracy is maintained at ±1.0% by in-line gravimetric checkweighing, and line speeds of 200–600 vials/min are typical for liquid filling. Batch release testing includes sterility per USP <71>, bacterial endotoxins per USP <85>, particulate matter per USP <788>, uniformity of dosage units per USP <905>, and container closure integrity per USP <1207>. The manufacturing environment is qualified under EU GMP Annex 1 and FDA 21 CFR 210/211. Terminal finished product types are aqueous injection vials, ampoules, and pre-filled syringes for intravenous, intramuscular, or subcutaneous administration.

Sterile injectable environment and release specifications:

When aqueous stability data show hydrolytic degradation of B.Infanti Pharma Grade API exceeding 1.0% per year at 25 °C, the sterile injectable presentation is converted to lyophilised powder. The pre-lyophilisation addition ratio is defined by the target dose per vial and fill volume: a 50.0 mg dose filled at 5.0 mL corresponds to 10.0 mg/mL, and a 200.0 mg dose filled at 10.0 mL corresponds to 20.0 mg/mL. Bulking agents are required to prevent cake collapse; mannitol is used at 2.0–5.0% w/v, and sucrose or trehalose at 1.0–10.0% w/v, keeping total solid content between 5.0–20.0% w/v. The collapse temperature of the formulation is measured by freeze-drying microscopy; the primary drying product temperature is held 3–5 °C below that value. Freezing is executed at −40 to −50 °C with controlled nucleation or annealing at −10 to −20 °C to reduce vial-to-vial ice crystal variability. Primary drying is run at chamber pressure 50–200 mTorr and shelf temperature −20 to −10 °C for 24–72 h depending on fill depth; secondary drying raises shelf temperature to 25–40 °C for 4–12 h until residual moisture is below 1.0% by Karl Fischer titration. Vials are stoppered under vacuum or partial nitrogen at 50–80% relative humidity below 30% to prevent rehydration. Release testing includes USP <1>, USP <921>, Ph. Eur. 2.2.32, sterility by USP <71>, and sub-visible particles by USP <788>. Published data for this specific configuration is limited; thermal characterisation by differential scanning calorimetry is therefore required before cycle scale-up. Terminal finished product types are lyophilised cake in serum vials for reconstitution, dual-chamber syringes, and lyophilised powders for intramuscular suspension after reconstitution.

For 0.8–1.2 mm Multiparticulate Pellets via Twin-Screw Extrusion

Extrusion-spheronisation is applied when B.Infanti Pharma Grade API is combined with microcrystalline cellulose to form dense pellet cores for modified-release or taste-masked multiparticulate capsules and sachets. The addition ratio is set by the desired dose in a single capsule or sachet fill: a 25.0 mg dose in a 500.0 mg pellet fill corresponds to 5.0% w/w, while a 150.0 mg dose in 300.0 mg pellet fill corresponds to 50.0% w/w. Microcrystalline cellulose is typically included at 30–50% w/w to provide plastic deformation and spheronisation substrate; binder solutions such as hypromellose 2.0–5.0% w/w are added to achieve wet mass consistency. Extrusion is performed on a twin-screw extruder with L/D ratio 20:1 through 0.8 mm screens at screw speed 50–150 rpm and torque 20–60% of maximum; spheronisation follows at plate speed 500–1000 rpm for 1–5 min, producing pellets with aspect ratio below 1.2. Pellets are dried in a fluid bed at 50–60 °C to LOD 1.0–2.0% and coated with ethylcellulose or methacrylic acid copolymer to modulate release. Dissolution is tested per USP <711> with multiple pH media; pellet size distribution is controlled by sieve analysis per Ph. Eur. 2.9.38, and residual solvent by ICH Q3C. Processing limitations include excess water above 35–45% w/w causing agglomeration in the extruder barrel and low torque below 15% indicating insufficient wetting. Terminal finished product types are pellet-filled hard capsules, multi-unit pellet systems in sachets, and dispersible pellet tablets.